Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation.

Virzì AR, Gentile A, Benvenuti S, Comoglio PM.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10058-10063. doi: 10.1073/pnas.1721147115. Epub 2018 Sep 17.

2.

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.

Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S.

Cell Metab. 2018 Aug 30. pii: S1550-4131(18)30507-2. doi: 10.1016/j.cmet.2018.08.006. [Epub ahead of print]

PMID:
30174307
3.

The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.

Miglio U, Berrino E, Panero M, Ferrero G, Coscujuela Tarrero L, Miano V, Dell'Aglio C, Sarotto I, Annaratone L, Marchiò C, Comoglio PM, De Bortoli M, Pasini B, Venesio T, Sapino A.

Int J Cancer. 2018 Aug 25. doi: 10.1002/ijc.31831. [Epub ahead of print]

PMID:
30144023
4.

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.

Basilico C, Modica C, Maione F, Vigna E, Comoglio PM.

Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31550. [Epub ahead of print]

PMID:
29693242
5.

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.

Comoglio PM, Trusolino L, Boccaccio C.

Nat Rev Cancer. 2018 Jun;18(6):341-358. doi: 10.1038/s41568-018-0002-y. Review.

PMID:
29674709
6.

RON tyrosine kinase mutations in brain metastases from lung cancer.

Milan M, Benvenuti S, Balderacchi AM, Virzì AR, Gentile A, Senetta R, Cassoni P, Comoglio PM, Stella GM.

ERJ Open Res. 2018 Mar 6;4(1). pii: 00083-2017. doi: 10.1183/23120541.00083-2017. eCollection 2018 Jan.

7.

Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.

Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzì AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, Durante C, Verrienti A.

Hum Mutat. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378. Epub 2017 Dec 20.

PMID:
29219214
8.

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Stella GM, Benvenuti S, Gentile A, Comoglio PM.

EBioMedicine. 2017 Oct;24:34-42. doi: 10.1016/j.ebiom.2017.09.025. Epub 2017 Sep 21. Review.

9.

A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.

Luraghi P, Bigatto V, Cipriano E, Reato G, Orzan F, Sassi F, De Bacco F, Isella C, Bellomo SE, Medico E, Comoglio PM, Bertotti A, Trusolino L, Boccaccio C.

Clin Cancer Res. 2018 Feb 15;24(4):807-820. doi: 10.1158/1078-0432.CCR-17-2151. Epub 2017 Oct 3.

PMID:
28974546
10.

Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.

Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, D'Ambrosio A, Comoglio PM, Finocchiaro G, Boccaccio C.

Stem Cells. 2017 Nov;35(11):2218-2228. doi: 10.1002/stem.2703. Epub 2017 Sep 29.

11.

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.

Mira A, Morello V, Céspedes MV, Perera T, Comoglio PM, Mangues R, Michieli P.

Oncotarget. 2017 Jun 13;8(24):38193-38213. doi: 10.18632/oncotarget.16942.

12.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27.

PMID:
27575023
13.

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S.

Oncogene. 2017 Mar 2;36(9):1200-1210. doi: 10.1038/onc.2016.283. Epub 2016 Aug 15.

PMID:
27524418
14.

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.

Pupo E, Ducano N, Lupo B, Vigna E, Avanzato D, Perera T, Trusolino L, Lanzetti L, Comoglio PM.

Cancer Res. 2016 Sep 1;76(17):5019-29. doi: 10.1158/0008-5472.CAN-15-3107. Epub 2016 Jun 30.

15.

MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.

De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, Reato G, Pellegatta S, Finocchiaro G, Perera T, Garibaldi E, Gabriele P, Comoglio PM, Boccaccio C.

EMBO Mol Med. 2016 May 2;8(5):550-68. doi: 10.15252/emmm.201505890. Print 2016 May.

16.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.

Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420.

17.

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Cignetto S, Modica C, Chiriaco C, Fontani L, Milla P, Michieli P, Comoglio PM, Vigna E.

Mol Oncol. 2016 Jun;10(6):938-48. doi: 10.1016/j.molonc.2016.03.004. Epub 2016 Mar 28.

18.

Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.

Sala V, Gallo S, Gatti S, Medico E, Vigna E, Cantarella D, Fontani L, Natale M, Cimino J, Morello M, Comoglio PM, Ponzetto A, Crepaldi T.

J Mol Cell Cardiol. 2016 Apr;93:84-97. doi: 10.1016/j.yjmcc.2016.02.017. Epub 2016 Feb 26.

PMID:
26924269
19.

Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals.

Lupo B, Vialard J, Sassi F, Angibaud P, Puliafito A, Pupo E, Lanzetti L, Comoglio PM, Bertotti A, Trusolino L.

BMC Biol. 2016 Jan 19;14:5. doi: 10.1186/s12915-016-0226-9.

20.

Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, Comoglio PM.

Mol Oncol. 2015 Nov;9(9):1760-72. doi: 10.1016/j.molonc.2015.05.007. Epub 2015 Jun 5.

21.

Activation of RAS family members confers resistance to ROS1 targeting drugs.

Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S.

Oncotarget. 2015 Mar 10;6(7):5182-94.

22.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A.

Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445.

23.

TNF-α promotes invasive growth through the MET signaling pathway.

Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, Sarotto I, Comoglio PM, Boccaccio C.

Mol Oncol. 2015 Feb;9(2):377-88. doi: 10.1016/j.molonc.2014.09.002. Epub 2014 Sep 26.

24.

MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure.

Boccaccio C, Comoglio PM.

Curr Opin Cell Biol. 2014 Dec;31:98-105. doi: 10.1016/j.ceb.2014.09.008. Epub 2014 Oct 8. Review.

PMID:
25305631
25.

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM 3rd, Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L, Michieli P.

Cancer Res. 2014 Nov 15;74(22):6598-609. doi: 10.1158/0008-5472.CAN-14-0761. Epub 2014 Sep 12.

26.

Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.

Martin V, Corso S, Comoglio PM, Giordano S.

Mol Oncol. 2014 Dec;8(8):1561-74. doi: 10.1016/j.molonc.2014.06.010. Epub 2014 Jun 24.

27.

MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells.

Boccaccio C, Luraghi P, Comoglio PM.

Cancer Res. 2014 Jul 15;74(14):3647-51. doi: 10.1158/0008-5472.CAN-14-1088. Epub 2014 Jul 1. Review.

28.

Targeting the oncogenic Met receptor by antibodies and gene therapy.

Vigna E, Comoglio PM.

Oncogene. 2015 Apr 9;34(15):1883-9. doi: 10.1038/onc.2014.142. Epub 2014 Jun 2. Review.

29.

Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy.

Gallo S, Gatti S, Sala V, Albano R, Costelli P, Casanova E, Comoglio PM, Crepaldi T.

Cell Death Dis. 2014 Apr 17;5:e1185. doi: 10.1038/cddis.2014.155.

30.

The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.

Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM.

Int J Cancer. 2014 Nov 15;135(10):2305-16. doi: 10.1002/ijc.28879. Epub 2014 Apr 15.

31.

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.

Rocci A, Gambella M, Aschero S, Baldi I, Trusolino L, Cavallo F, Gay F, Larocca A, Magarotto V, Omedè P, Isaia G, Bertotti A, Liberati AM, Catalano L, De Rosa L, Musto P, Vallone R, Falcone A, Drandi D, Ladetto M, Comoglio PM, Boccadoro M, Palumbo A.

Br J Haematol. 2014 Mar;164(6):841-50. doi: 10.1111/bjh.12719. Epub 2014 Jan 23.

32.

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C.

Cancer Res. 2014 Mar 15;74(6):1857-69. doi: 10.1158/0008-5472.CAN-13-2340-T. Epub 2014 Jan 21.

33.

Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics.

Stella GM, Luisetti M, Pozzi E, Comoglio PM.

Lancet Respir Med. 2013 May;1(3):251-61. doi: 10.1016/S2213-2600(13)70009-2. Epub 2013 Mar 1. Review.

PMID:
24429131
34.

An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.

Benvenuti S, Gentile A, Lazzari L, Arnesano A, Trusolino L, Comoglio PM.

Mol Oncol. 2014 Mar;8(2):378-88. doi: 10.1016/j.molonc.2013.12.006. Epub 2013 Dec 18.

35.

Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Vigna E, Pacchiana G, Chiriaco C, Cignetto S, Fontani L, Michieli P, Comoglio PM.

J Mol Med (Berl). 2014 Jan;92(1):65-76. doi: 10.1007/s00109-013-1079-0. Epub 2013 Sep 7.

36.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

37.

The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target.

Boccaccio C, Comoglio PM.

Cancer Res. 2013 Jun 1;73(11):3193-9. doi: 10.1158/0008-5472.CAN-12-4039. Epub 2013 May 21. Review.

38.

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C.

Cancer Res. 2012 Sep 1;72(17):4537-50. doi: 10.1158/0008-5472.CAN-11-3490. Epub 2012 Jun 26.

39.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.

Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.

40.

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L.

Oncogene. 2013 Mar 14;32(11):1428-40. doi: 10.1038/onc.2012.154. Epub 2012 May 7.

41.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5.

42.

MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer.

Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S.

Clin Cancer Res. 2012 Feb 1;18(3):737-47. doi: 10.1158/1078-0432.CCR-11-1699. Epub 2011 Dec 16.

43.

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. doi: 10.1073/pnas.1017536108. Epub 2011 Aug 9.

44.

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.

Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM, Trusolino L, Bertotti A.

Int J Cancer. 2012 Mar 15;130(6):1357-66. doi: 10.1002/ijc.26137. Epub 2011 May 30.

45.

Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.

Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM.

Cancer Res. 2011 Apr 15;71(8):3132-41. doi: 10.1158/0008-5472.CAN-10-2662. Epub 2011 Apr 12.

46.

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C.

J Natl Cancer Inst. 2011 Apr 20;103(8):645-61. doi: 10.1093/jnci/djr093. Epub 2011 Apr 4.

47.

Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2011 May 15;17(10):3146-56. doi: 10.1158/1078-0432.CCR-10-3377. Epub 2011 Mar 29.

48.

Ron kinase transphosphorylation sustains MET oncogene addiction.

Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM.

Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6.

49.

MET signalling: principles and functions in development, organ regeneration and cancer.

Trusolino L, Bertotti A, Comoglio PM.

Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. doi: 10.1038/nrm3012. Review.

50.

MET mutations in cancers of unknown primary origin (CUPs).

Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, Senetta R, Venesio T, Pozzi E, Bardelli A, Comoglio PM.

Hum Mutat. 2011 Jan;32(1):44-50. doi: 10.1002/humu.21374. Epub 2010 Nov 9.

Supplemental Content

Loading ...
Support Center